[Progressive supranuclear palsy].

Progressive supranuclear palsy (PSP) is a heterogeneous progressive neurodegenerative disease characterized by onset after 50 years old, Parkinson's syndrome, early development of postural instability, absence or transient reaction to levodopa drugs, neuropsychological disorders, dysphagia and dysarthria and eye movement disorders. The review provides an analysis of modern data on etiology, clinical presentation, differential diagnosis of the disease. The morphological picture and neuroimaging features, as well as modern ideas about treatment, are described.

[The use of piribedil in early and late stages of Parkinson's disease].

In this article, we present clinical cases at an early stage of Parkinson's disease with mild affective and cognitive disorders, and at a later stage with motor fluctuations and levodopa-induced dyskinesia. The efficacy of dopamine receptor agonists in treatment of Parkinson's disease in the early and late stages is illustrated by the example of piribedil.

[Nocturnal symptoms of Parkinson's disease and approaches to their correction].

Seventy-three patients with Parkinson's disease were enrolled. Patients were stratified into 2 groups by the presence (53 patients) or absence (20 patients) of nocturnal symptoms. A control group included 10 healthy people.

[Nocturnal motor symptoms of Parkinson's disease and their treatment with the three-component drug levodopa/carbidopa/entacapone].

Nocturnal symptoms are integral part of the general clinical picture of Parkinson's disease (PD). They are subdivided into non-motor and motor symptoms, the latter included night akinesia, crampi, night akathisia, dystonia, restless leg syndrome (RLS), periodic movements of limbs (PML) and psychomotor agitation during sleep. We have studied 53 patients with PD and evaluated the frequency of these disturbances as follows: night akinesia (42.

[Stalevo (levodopa/carbidopa/entacapon)--a new generation drug in the treatment of Parkinson's disease].

Based on literature data on the usage of Dopa medications in the treatment of Parkinson's disease (PD), a characteristic of a new complex drug stalevo, which includes levodopa, carbidopa and entacapon (catechol-O-methyltransferase inhibitor), is presented. The authors studied 15 patients with PD, aged 55.6+/-8.